Results 101 to 110 of about 27,207 (241)

Pulmonary Vascular Endothelial Cells in Lung Diseases: Mechanisms, Therapeutic Strategies, and Future Directions

open access: yesCell Proliferation, EarlyView.
The pathogenic mechanisms of pulmonary vascular endothelial cells (VECs) in lung diseases and their multimodal therapeutic strategies. ABSTRACT Pulmonary vascular endothelial cells (VECs) are essential for the normal function of the lung, through maintaining vascular barrier integrity, regulating blood flow, and participating in inflammatory responses ...
Qianyue Liu   +5 more
wiley   +1 more source

Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a

open access: yesNature Communications, 2017
Complement C3a is an important protein in innate and adaptive immunity, but its roles in vivo are unclear. Here the authors develop novel chemical agonists and antagonists for the C3a receptor, and show that they modulate mast cell degranulation and ...
Rink-Jan Lohman   +13 more
doaj   +1 more source

The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement‐dependent cytotoxicity

open access: yesThe FEBS Journal, EarlyView.
Multimeric IgM‐fragment crystallizable region (Fc) fragments retain the ability to bind C1q and initiate the classical complement pathway, leading to C4 activation and deposition in vitro. However, the Fc cores can also inhibit complement‐dependent cytotoxicity by competing with surface‐bound antibodies for C1q engagement.
Andrea J. Pinto   +9 more
wiley   +1 more source

Complement activation by the artificial surface of cardiopulmonary bypass is a persistent clinical problem

open access: yesScientific Reports
Activation of the alternative complement pathway by artificial extracorporeal surfaces is relevant to several clinical applications such as cardiac surgery with cardiopulmonary bypass (CPB), thoracic organ transplantation and hemodialysis.
Joel David Bierer   +8 more
doaj   +1 more source

Paths reunited: initiation of the classical and lectin pathways of complement activation [PDF]

open access: yes, 2010
Understanding the structural organisation and mode of action of the initiating complex of the classical pathway of complement activation (C1) has been a central goal in complement biology since its isolation almost 50 years ago.
Keeble, Anthony H.   +4 more
core   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai   +4 more
wiley   +1 more source

New Hydrophilic Helixone Dialyzers as an Alternative for Hemodialysis Patients With Membrane Hypersensitivity Reactions: A Retrospective Single‐Cohort Study

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background Synthetic dialysis membranes, particularly those composed of polysulfone blended with polyvinylpyrrolidone, are commonly used in hemodialysis due to their efficiency. However, hypersensitivity reactions—often atypical and not fitting traditional type A and B classifications—have increasingly been reported.
Víctor Joaquín Escudero‐Saiz   +9 more
wiley   +1 more source

Indoor microbial exposure increases complement component C3a and C-reactive protein concentrations in serum

open access: yesHeliyon
Indoor exposure to microbial growth, caused by moisture damage, has been an established health risk for several decades. It is likely that a damp indoor environment contains biological pollutants that trigger both the innate and adaptive branches of the ...
Outi Karhuvaara   +4 more
doaj   +1 more source

Enzymatic Reactions and Detection of C3 Cleavage Fragments

open access: yesBio-Protocol, 2014
The complement component C3 is the major effector molecule of the complement system. C3 circulates in the blood and interstitial fluids as pro-enzyme and is activated by enzymatic cleavage into a C3a portion, a classic anaphylatoxin that functions as ...
Claudia Kemper, Martin Kolev
doaj   +1 more source

First successful protocol for desensitization to eptinezumab

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Eptinezumab is an anti‐calcitonin gene‐related peptide monoclonal antibody used for migraine prevention. During clinical trials, hypersensitivity to eptinezumab was described without a clear underlying mechanism. To determine if the reaction was immunoglobulin E–mediated, the team of Nice University Hospital (Nice, France) performed
Benoit Gerard   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy